CoChat

Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation

Open access
Martin, Eric S., Belmont, Peter J., Sinnamon, Mark J., Richard, Larissa Georgeon, Yuan, Jing, Coffee, Erin M., Roper, Jatin, Lee, Lydia, Heidari, Pedram, Lunt, Sophia Y., Goel, Gautam, Ji, Xiadong, Xie, Zhi, Xie, Tao, Lamb, John, Weinrich, Scott L., VanArsdale, Todd, Bronson, Roderick T., Xavier, Ramnik J., Vander Heiden, Matthew G., Kan, Julie L. C., Mahmood, Umar, Hung, Kenneth E. · 2013 · Clinical Cancer Research
Cited by 37

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: Effective therapies for KRAS-mutant colorectal cancer (CRC) are a critical unmet clinical need. Previously, we described genetically engineered mouse models (GEMM) for sporadic Kras-mutant and non-mutant CRC suitable for preclinical evaluation of experimental therapeutics. To accelerate drug discovery and validation, we sought to derive low-passage cell lines from GEMM Kras-mutant and wild-type tumors for in vitro screening and transplantation into the native colonic environment of immunocompetent mice for in vivo validation. Experimental Design: Cell lines were derived from Kras-mutant and non-mutant GEMM tumors under defined media conditions. Growth kinetics, phosphoproteomes, transcriptomes, drug sensitivity, and metabolism were examined. Cell lines were implanted in mice and monitored for in vivo tumor analysis. Results: Kras-mutant cell lines displayed increased proliferation, mitogen-activated protein kinase signaling, and phosphoinositide-3 kinase signaling. Microarray analysis identified significant overlap with human CRC-related gene signatures, including KRAS-mutant and metastatic CRC. Further analyses revealed enrichment for numerous disease-relevant biologic pathways, including glucose metabolism. Functional assessment in vitro and in vivo validated this finding and highlighted the dependence of Kras-mutant CRC on oncogenic signaling and on aerobic glycolysis. Conclusions: We have successfully characterized a novel GEMM-derived orthotopic transplant model of human KRAS-mutant CRC. This approach combines in vitro screening capability using low-passage cell lines that recapitulate human CRC and potential for rapid in vivo validation using cell line-derived tumors that develop in the colonic microenvironment of immunocompetent animals. Taken together, this platform is a clear advancement in preclinical CRC models for comprehensive drug discovery and validation efforts. Clin Cancer Res; 19(11); 2929–40. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-2307

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 37

Metadata

Authors
Martin, E. S., Belmont, P. J., Sinnamon, M. J., Richard, L. G., Yuan, J., Coffee, E. M., Roper, J., Lee, L., Heidari, P., Lunt, S. Y., Goel, G., Ji, X., Xie, Z., Xie, T., Lamb, J., Weinrich, S. L., VanArsdale, T., Bronson, R. T., Xavier, R. J., Vander Heiden, M. G., Kan, J. L. C., Mahmood, U., & Hung, K. E.
Venue
Clinical Cancer Research
Published
2013-05-30
Volume
19
Issue
11
Pages
2929-2940
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1550017134
Cited by
37
References
9
FWCI
3.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-2307
The paper
Martin, E. S., Belmont, P. J., Sinnamon, M. J., Richard, L. G., Yuan, J., Coffee, E. M., Roper, J., Lee, L., Heidari, P., Lunt, S. Y., Goel, G., Ji, X., Xie, Z., Xie, T., Lamb, J., Weinrich, S. L., VanArsdale, T., Bronson, R. T., Xavier, R. J., . . . Hung, K. E. (2013). Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-2307

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.